Therapies for Children With Autism Spectrum Disorders

Evidence Table. Therapies for children with ASD (continued)
Study
Inclusion/ Exclusion Baseline
Description Intervention
Criteria/ Population Measures Outcomes
analysts
G2: 36.4 ± 5.9
G1: 67.8 ± 10.1 MSEL fine motor
Assessment:
Maternal age, years ± SD: G2: 67.6 ± 6.4 score, 1 year,
ADI-R, ADOS, MSEL, G1: 32.5 ± 5.4
VABS daily living mean ± SD:
VABS, changes in the G2: 33.7 ± 5
score, mean ± SD: G1: 30 ± 13
severity of stereotyped
G1: 68.3 ± 6.9 G2: 35.9 ± 15.9
behaviors.
G2: 69.3 ± 5.9 G1/BL: P = NS
Measure of treatment
fidelity reported:
No
G2/BL: P = NS
Itzchak et al., Co-interventions held
VABS motor skills
2009 (continued) stable during treatment:
score, 1 year,
NR
mean ± SD:
Concomitant therapies:
G1: 75.6 ± 13.1
NR
G2: 80.9 ± 16.3
N at enrollment:
G1/BL: P < 0.001
G1: 53
G2/BL: P = NS
G2: 15
Adaptive
N at follow-up:
behavior:
G1: 53
VABS communi-
G2: 15
cation score, 1
year, mean ± SD:
G1: 72.3 ± 16.1
G2: 82.2 ± 12.9
G1/BL: P < 0.05
G2/BL: P < 0.001
VABS daily living
score, 1 year,
mean ± SD:
G1: 69.2 ± 7.9
G2: 75.4 ± 13.3
G1/BL: P = NS
G2/BL: P = NS
Harms:
NR
Modifiers:
There was a
significant (time X
group) interaction
in the ADOS
stereotyped
behaviors score
(P < 0.05); a significant
decrease
in stereotyped
behavior and
restricted interests
was noted for G1
(P < 0.000) but
not for G2.
Author:
Intervention:
Inclusion criteria: Problem behavior: Problem
Akhondzadeh et Piracetam, titrated up to • Age 3-11 years ABC-C total score, behavior:
al., 2008
Country:
800 mg/day (200 mg/day • Diagnosis of autism
starting dose with 200 mg Exclusion criteria:
mean ± SD:
G1: 23.15 ± 5.80
ABC-C total
score, week 10,
Iran
Practice
setting:
Academic
increments every 2 days)
Risperidone, dosage by
weight:
• 10-40 kg: titrated up to
• Previously received G2: 24.00 ± 8.25
neuroleptics or any G1/G2: P = 0.70
psychotropic drug
treatment 6 months prior
mean change ±
SD:
G1: -11.9 ± 3.79
G2: -5.15 ± 3.04
C-114